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Alzheimer’s disease (AD) is a multifactorial age-related disease associated with oxidative
stress (OS) and impaired cholinergic transmission. Accordingly, targeting mitochondrial
OS and restoring cholinergic transmission can be an effective therapeutic strategy toward
AD. Herein, we report for the first time dual-target hydroxybenzoic acid (HBAc) derivatives
acting as mitochondriotropic antioxidants and cholinesterase (ChE) inhibitors. The
studies were performedwith twomitochondriotropic antioxidantsAntiOxBEN1 (catechol
derivative), and AntiOxBEN2 (pyrogallol derivative) and compounds 15–18, which have
longer spacers. Compounds AntiOxBEN1 and 15, with a shorter carbon chain spacer
(six- and eight-carbon) were shown to be potent antioxidants and BChE inhibitors
(IC50 = 85 ± 5 and 106 ± 5 nM, respectively), while compounds 17 and 18 with a
10-carbon chain weremore effective AChE inhibitors (IC50 = 7.7± 0.4 and 7.2± 0.5µM,
respectively). Interestingly, molecular modeling data pointed toward bifunctional ChEs
inhibitors. The most promising ChE inhibitors acted by a non-competitive mechanism. In
general, with exception of compounds 15 and 17, no cytotoxic effects were observed in
differentiated human neuroblastoma (SH-SY5Y) and human hepatocarcinoma (HepG2)
cells, while Aβ-induced cytotoxicity was significantly prevented by the new dual-target
HBAc derivatives. Overall, due to its BChE selectivity, favorable toxicological profile,
neuroprotective activity and drug-like properties, which suggested blood-brain barrier
(BBB) permeability, the mitochondriotropic antioxidantAntiOxBEN1 is considered a valid
lead candidate for the development of dual acting drugs for AD and other mitochondrial
OS-related diseases.
Keywords: hydroxybenzoic acids, oxidative stress, mitochondria-targeted antioxidants, cholinesterase inhibitors,
acetyl and butyrylcholinesterase
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INTRODUCTION
Alzheimer’s disease (AD) is a multifactorial age-related disease,
closely associated with impaired cholinergic transmission and
oxidative stress (OS), among other factors (Guo et al., 2013;
Zheng et al., 2014; Talevi, 2015; Nikolic et al., 2016). According
to the cholinergic hypothesis, impairment in the cholinergic
function is of critical importance in AD, especially in brain
areas like the neocortex and the hippocampus, which control
learning, memory, behavior and emotional responses. The levels
of acetylcholine (ACh) in the synaptic cleft are tightly regulated
by cholinesterases enzymes (ChEs): acetylcholinesterase (AChE)
and butyrylcholinesterase (BChE) are the key regulators of
cholinergic tone and transmission (Anand and Singh, 2013;
Colović et al., 2013). While AChE in the healthy brain
predominates, BChE is considered to play a minor role in
the regulation of synaptic ACh levels (Li et al., 2017; Shah
et al., 2017). However, in advanced stages of AD, AChE activity
may decrease approximately by 50% in distinctive regions of
the brain while BChE activity is enhanced, making both ChEs
stimulating targets for the treatment of AD (Li et al., 2017;
Shah et al., 2017). Moreover, it was proposed that low-activity
BChE in AD patients correlates with better cognitive function
(Holmes et al., 2005). Additionally, it has been shown that
ChEs are proteins that colocalize with Aβ deposits and directly
promotes Aβ assembly and aggregation into insoluble plaques,
a classic biochemical hallmark of AD pathology (Morán et al.,
1993). These secondary non-cholinergic functions of ChEs are
attributed to the peripheral active site (PAS) of the enzyme’s active
site (Bajda et al., 2013; Silva et al., 2014). While deposition of Aβ
plaques is the hallmark of the disease, the neurotoxicity of Aβ
oligomers was shown to be stronger than that of the fibrils.
Brain is highly vulnerable to OS due to its high-energy
demand and oxygen exposure, rich abundance of easily
oxidizable polyunsaturated fatty acids, high level of potent
reactive oxygen species (ROS), and relative paucity of
endogenous antioxidants. OS and mitochondrial damage
have been implicated in the pathogenesis of several age-related
diseases (Guo et al., 2013). The redox alterations promoted
by OS in specific cellular components lead to a more oxidized
state, often resulting from an increased production of ROS
and/or more limited intrinsic antioxidant activity (Dai et al.,
Abbreviations: ABTS•+, 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic
acid); ACh, Acetylcholine; AChE, acetylcholinesterase; AD, Alzheimer’s
disease; ATCI, Acetylthiocholine iodide; BBB, blood-brain barrier; BCh,
butyrylcholine; BChE, butyrylcholinesterase; BTCI, butyrylthiocholine iodide;
ChEs, cholinesterases; clogP, logarithm of the octanol-water partition coefficient;
CNS, central nervous system; DIPEA, N,N-diisopropylethylamine; Diphos, 1,2-
bis(diphenylphosphine)ethane; DPPH•, 2,2′-diphenyl-1-picrylhydrazyl radical;
DTNB, 5,5′-dithiobis-(2-nitrobenzoate); EDTA, ethylenediaminetetraacetic acid;
FDA, Food and Drug Administration; GA, gallic acid; HBA, number of hydrogen
acceptors; HBAc, hydroxybenzoic acid(s); HBD, number of hydrogen donors;
HBSS, Hank’s balanced salt solution; Ki, inhibition constant; Km, Michaelis
constant; log BB, blood (plasma)-brain partitioning; NEAA, nonessential amino
acids; nrotb, number of rotatable bonds; OS, oxidative stress; PA, protocatechuic
acid; PPh3, triphenylphosphine; ROS, reactive oxygen species; TNB2−, anion
5-thio-2-nitrobenzoate; TPA, 12-O-Tetradecanoylphorbol-13-acetate; TPP+,
triphenylphosphonium cation; tPSA, topological polar surface area; Vmax ,
maximum velocity; 19 , transmembrane electric potential.
2014; Dhawan, 2014; Bhat et al., 2015; Ksiazek-Winiarek and
Głabinski, 2015). Therefore, it is believed that antioxidant
therapy can operate as a pharmacological approach to prevent or
delay the OS events that lead to neurodegeneration.
The fact that several drugs exert their effect through the
interaction with diverse targets is shifting the drug discovery
paradigm from the one target to a multiple-target approach. This
approach is becoming increasingly important in drug discovery
for multifactorial diseases, such as AD. As such, looking for new
chemical entities that can minimize OS and restore cholinergic
transmission by targeting ChEs can be a valid pharmacological
strategy for the clinical management of AD.
Protocatechuic (PA, Figure 1) and gallic acids (GA, Figure 1)
are hydroxybenzoic acids (HBAc) widely distributed in plants
and fruit with diverse biological properties such as antioxidant,
anti-inflammatory, antimicrobial and anticancer activity, as
well as neuroprotection (Heleno et al., 2015; Pezzini et al.,
2017; Szwajgier et al., 2017). Although this type of dietary
antioxidants has promising in vitro outcomes, the translation in
antioxidant therapy have had a dissatisfying clinical outcome,
which has been directly associated with poor bioavailability,
particularly inefficient cellular uptake and target selectivity
(Guzman-Villanueva et al., 2015). To address this limitation,
targeting mitochondria with organelle-specific molecules can be
a useful therapeutic strategy for the prevention and/or treatment
of OS-related diseases such as AD.
The design and synthesis of two mitochondriotropic
antioxidants based on HBAc (AntiOxBEN1 and AntiOxBEN2,
Figure 1), in which PA and GA were covalently bound
to a triphenylphosphonium cation (TPP+) through a six-
carbon aliphatic chain has been previously reported (Teixeira
et al., 2017b). AntiOxBENs effectively accumulated in rat
liver mitochondria, driven by the negative-inside organelle
transmembrane electric potential (19), and prevented lipid
peroxidation while exhibiting low toxicity (Teixeira et al.,
2017b). AntiOxBENs presented higher lipophilicity than the
parent compounds (PA and GA), and similar antioxidant and
iron chelating properties.
As part of our drug discovery program, and following an
AD multi-target strategy, AntiOxBEN1 and AntiOxBEN2 were
screened in this work toward ChEs. To perform structure-activity
relationship studies the series was extended (Figure 1) and the
antioxidant profile in cell free and cell-based systems as well
as the inhibitory activities toward AChE and BChE of the new
derivatives were evaluated. The cytotoxicity profile, drug-like
properties and mechanism of enzymatic inhibition were also
assessed. Moreover, to understand the enzyme(s)-inhibitor(s)
interactions, molecular modeling studies were performed using
models based in the crystal structures of the targets.
MATERIALS AND METHODS
Chemistry
Reagents and General Conditions
All reagents were purchased from Sigma-Aldrich and TCI
Chemicals. All solvents were pro analysis grade from Merck,
Carlo Erba Reagents and Scharlab.
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FIGURE 1 | Rational design followed to develop novel dual target agents (ChE inhibitors and mitochondriotropic antioxidants).
Thin layer chromatography (TLC) was performed on
precoated silica gel 60 F254 acquired from Merck with layer
thickness of 0.2mm. Reaction control was monitored using
ethyl acetate and/or ethyl acetate:methanol (9:1) and spots were
visualized under UV detection at 254 and 366 nm. Following the
extraction step, the organic layers were dried over anhydrous
sodium sulfate. Flash column chromatography was carried out
with silica gel 60 0.040–0.063mm acquired from Carlo-Erba
Reactifs. Cellulose flash column chromatography was carried
out with cellulose powder 0.01–0.10mm acquired from Sigma-
Aldrich. The elution systems used for flash chromatography were
specified for each compound. Solvents were evaporated using a
Büchi Rotavapor.
Apparatus
NMR data were acquired on a Bruker Avance III 400 NMR
spectrometer, at room temperature, operating at 400.15 MHz
for 1H and 100.62 MHz for 13C and DEPT135 (Distortionless
Enhancement by Polarization Transfer). Tetramethylsilane
(TMS) was used as internal reference; chemical shifts (δ) were
expressed in ppm and coupling constants (J) were given in Hz.
DEPT135 values were included in 13C NMR data (underline
values).
Mass spectra (MS) were carried out on a Varian 320-MS (EI)
or BrukerMicrotof (ESI) apparatus; the data were reported asm/z
(% of relative intensity of the most important fragments).
Synthesis of Benzoic Based Derivatives
General procedure used to obtain benzoic acid amide
derivatives (3–6).
The appropriate benzoic acid (3,4-dimethoxybenzoic acid (1)
or 3,4,5-trimethoxybenzoic acid (2), 1 mmol) was dissolved in
dichloromethane (15mL) and POCl3 (1 mmol) was added at
room temperature. After 30min, the reactional mixture was
cooled (ice bath) and 8-aminooctan-1-ol or 10-aminodecan-1-
ol (1.2 mmol) and DIPEA (4 mmol) were added. The reaction
was stirred for 1–2 h at room temperature. The mixture was
extracted with dichloromethane (3 × 20mL). The organic
phases were combined, washed with water, NaHCO3 5% (20mL)
and HCl 1M (20mL). The organic phases were combined,
dried and, after filtration, the solvent was evaporated and
the compound purified by silica gel flash chromatography
using ethyl acetate as eluting system. The fractions containing
the intended compound were collected and the solvent was
evaporated to dryness. The reaction was followed by TLC (silica
gel, ethyl acetate). The procedure was adapted from the literature
(Chen et al., 2013).
N-(8-Hydroxyoctyl)-3,4-dimethoxybenzamide (3). η = 49%.
1H RMN (CDCl3): δ = 1.29–1.38 (8H, m, N(CH2)2(CH2)4),
1.51–1.61 (4H, m, NCH2CH2(CH2)4CH2), 1.63 (1H, s, OH),
3.37–3.47 (2H, m, NCH2), 3.62 (2H, t, J = 6.6Hz, CH2O),
3.91 (6H, s, 2 × OCH3), 6.19 (1H, s, NH), 6.84 (1H, d,
J = 8.4Hz, H(5)), 7.25 (1H, dd, J = 2.0, 8.4Hz, H(6)), 7.41 (1H, d,
J = 2.0Hz, H(2)). 13C RMN (CDCl3): δ = 25.8 (N(CH2)5CH2),
27.0 (N(CH2)2CH2), 29.3 (N(CH2)3CH2), 29.4 (N(CH2)4CH2),
29.8 (NCH2CH2), 32.8 (N(CH2)6CH2), 40.2 (NCH2), 56.1 (2 ×
OCH3), 63.0 (CH2O), 110.4 (C(5)), 110.8 (C(2)), 119.2 (C(6)),
127.6 (C(1)), 149.1 (C(3)), 151.7 (C(4)), 167.2 (CO). ESI/MS m/z
(%): 332 ([M+Na]+, 100), 310 ([M+H]+, 67), 165 (97).
N-(8-Hydroxyoctyl)-3,4,5-trimethoxybenzamide (4). η = 71%.
1H RMN (CDCl3): δ = 1.28–1.42 (8H, m, N(CH2)2(CH2)4),
1.49–1.66 (4H, m, NCH2CH2(CH2)4CH2), 1.73 (1H, s, OH),
3.37–3.49 (2H, m, NCH2), 3.62 (2H, t, J = 6.6Hz, CH2O), 3.87
(3H, s, OCH3), 3.89 (6H, s, 2 × OCH3), 6.16 (1H, s, NH),
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6.98 (2H, s, H(2) and H(6)). 13C RMN (CDCl3): δ = 25.8
(N(CH2)5CH2), 27.0 (N(CH2)2CH2), 29.3 (N(CH2)3CH2), 29.4
(N(CH2)4CH2), 29.8 (NCH2CH2), 32.8 (N(CH2)6CH2), 40.3
(NCH2), 56.5 (2 × OCH3), 61.0 (OCH3), 63.1 (CH2O), 104.5
(C(2) andC(6)), 130.5 (C(1)), 141.0 (C(4)), 153.3 (C(3) andC(5)),
167.4 (CO). ESI/MSm/z (%): 362 ([M+Na]+, 57), 340 ([M+H]+,
98), 195 (100), 154 (54).
N-(10-Hydroxydecyl)-3,4-dimethoxybenzamide (5). η = 54%.
1H RMN (CDCl3): δ = 1.24–1.35 (12H, m, N(CH2)2(CH2)6),
1.50–1.60 (4H, m, NCH2CH2(CH2)6CH2), 1.61 (1H, s, OH),
3.36–3.46 (2H, m, NCH2), 3.62 (2H, t, J = 6.6Hz, CH2O),
3.90 (6H, s, 2 × OCH3), 6.17 (1H, s, NH), 6.84 (1H, d,
J = 8.4Hz, H(5)), 7.25 (1H, dd, J = 2.0, 8.4Hz, H(6)), 7.41
(1H, d, J = 2.0Hz, H(2)). 13C RMN (CDCl3): δ = 25.8
(N(CH2)7CH2), 27.1 (N(CH2)2CH2), 29.4 (N(CH2)3CH2),
29.5 (N(CH2)4CH2CH2CH2), 29.6 (N(CH2)5CH2), 29.8
(NCH2CH2), 32.9 (N(CH2)8CH2), 40.2 (NCH2), 56.1 (2 ×
OCH3), 63.1 (CH2O), 110.4 (C(5)), 110.8 (C(2)), 119.2 (C(6)),
127.7 (C(1)), 149.1 (C(3)), 151.7 (C(4)), 167.2 (CO). ESI/MS m/z
(%): 360 ([M+Na]+, 43), 338 ([M+H]+, 61), 165 (100).
N-(10-Hydroxydecyl)-3,4,5-trimethoxybenzamide (6).
η = 71%. 1H RMN (CDCl3): δ = 1.23–1.36 (12H, m,
N(CH2)2(CH2)6), 1.49–1.62 (4H, m, NCH2CH2(CH2)6CH2),
1.64 (1H, s, OH), 3.36–3.49 (2H, m, NCH2), 3.63 (2H, t,
J = 6.6Hz, CH2O), 3.86 (3H, s, OCH3), 3.89 (6H, s, 2 ×
OCH3), 6.11 (1H, s, NH), 6.98 (2H, s, H(2) and H(6)). 13C
RMN (CDCl3): δ = 25.8 (N(CH2)7CH2), 27.1 (N(CH2)2CH2),
29.4 (N(CH2)3CH2), 29.5 (N(CH2)4CH2CH2CH2), 29.6
(N(CH2)5CH2), 29.8 (NCH2CH2), 32.9 (N(CH2)8CH2), 40.4
(NCH2), 56.5 (2 × OCH3), 61.0 (OCH3), 63.1 (CH2O), 104.5
(C(2) and C(6)), 130.5 (C(1)), 141.0 (C(4)), 153.3 (C(3) and
C(5)), 167.4 (CO). ESI/MS m/z (%): 368 ([M+H]+, 100), 195
(98), 169 (22), 154 (51).
General procedure used to obtain bromo derivatives (7–10)
Benzoic acid amide derivative (3–6) (1 mmol) and 1,2-
dibromotetrachloroethane (1 mmol) were dissolved in THF
(20mL). After, 1,2-bis(diphenylphosphine)ethane (diphos) (0.5
mmol) was added and the reaction was stirred at room
temperature for 20 h. Then, the reaction mixture was filtered
using a Celite pad. After evaporation of the filtrate, an oil
residue was obtained. The oil was purified by silica gel flash
chromatography using ethyl acetate as eluting system. The
fractions containing the intended compound were collected.
After the solvent evaporation, the compound was recrystallized
from n-hexane. The reaction was followed by TLC (silica gel,
ethyl acetate). The procedure was adapted from the literature
(Pollastri et al., 2001; Teixeira et al., 2017b).
N-(8-Bromooctyl)-3,4-dimethoxybenzamide (7). η = 64%. 1H
RMN (CDCl3): δ = 1.30–1.45 (8H, m, N(CH2)2(CH2)4), 1.55–
1.65 (2H, m, NCH2CH2), 1.79–1.89 (2H, m, N(CH2)6CH2), 3.39
(2H, t, J = 6.8Hz, CH2Br), 3.40–3.45 (2H, m, NCH2), 3.91 (6H,
s, 2 × OCH3), 6.12 (1H, s, Hz, NH), 6.84 (1H, d, J = 8.4Hz,
H(5)), 7.25 (1H, dd, J = 2.0, 8.4Hz, H(6)), 7.42 (1H, d, J = 2.0Hz,
H(2)). 13C RMN (CDCl3): δ = 27.0 (N(CH2)2CH2), 28.2
(N(CH2)5CH2), 28.8 (N(CH2)4CH2), 29.2 (N(CH2)3CH2), 29.8
(NCH2CH2), 32.9 (N(CH2)6CH2), 34.1 (CH2Br), 40.2 (NCH2),
56.1 (2 × OCH3), 110.4 (C(5)), 110.8 (C(2)), 119.2 (C(6)), 127.7
(C(1)), 149.2 (C(3)), 151.8 (C(4)), 167.2 (CO). ESI/MS m/z (%):
396 ([M+Na+2]+, 30), 394 ([M+Na]+, 30), 374 ([M+H+2]+,
100), 372 ([M+H]+, 91), 165 (32), 139 (27), 124 (40).
N-(8-Bromooctyl)-3,4,5-trimethoxybenzamide (8). η = 69%.
1H RMN (CDCl3): δ = 1.27–1.47 (8H, m, N(CH2)2(CH2)4),
1.56–1.65 (2H,m, NCH2CH2), 1.79–1.90 (2H,m, N(CH2)6CH2),
3.40 (2H, t, J = 6.8Hz, CH2Br), 3.41–3.47 (2H, m, NCH2),
3.87 (3H, s, OCH3), 3.89 (6H, s, 2 × OCH3), 6.12 (1H, s, NH),
6.98 (2H, s, H(2) and H(6)). 13C RMN (CDCl3): δ = 27.0
(N(CH2)2CH2), 28.2 (N(CH2)5CH2), 28.8 (N(CH2)4CH2), 29.2
(N(CH2)3CH2), 29.8 (NCH2CH2), 32.8 (N(CH2)6CH2), 34.1
(CH2Br), 40.3 (NCH2), 56.5 (2 × OCH3), 61.0 (OCH3), 104.5
(C(2) and C(6)), 130.4 (C(1)), 141.0 (C(4)), 153.3 (C(3) and
C(5)), 167.4 (CO). ESI/MS m/z (%): 426 ([M+Na+2]+, 35), 424
([M+Na]+, 39), 404 ([M+H+2]+, 78), 402 ([M+H]+, 93), 195
(26), 169 (25), 154 (100).
N-(10-Bromodecyl)-3,4-dimethoxybenzamide (9). η = 62%.
1H RMN (CDCl3): δ = 1.24–1.44 (12H, m, N(CH2)2(CH2)6),
1.55–1.66 (2H,m, NCH2CH2), 1.78–1.88 (2H,m, N(CH2)8CH2),
3.39 (2H, t, J = 6.9Hz, CH2Br), 3.41–3.46 (2H, m, NCH2), 3.90
(6H, s, 2 × OCH3), 6.83 (1H, d, J = 8.4Hz, H(5)), 7.30 (1H, dd,
J = 2.0, 8.4Hz, H(6)), 7.42 (1H, d, J = 2.0Hz, H(2)). 13C RMN
(CDCl3): δ = 27.1 (N(CH2)2CH2), 28.2 (N(CH2)7CH2), 28.8
(N(CH2)6CH2), 29.4 (N(CH2)3CH2), 29.5 (N(CH2)4(CH2)2),
29.7 (NCH2CH2), 32.9 (N(CH2)8CH2), 34.1 (CH2Br), 40.6
(NCH2), 56.2 (2 × OCH3), 110.4 (C(5)), 110.9 (C(2)), 119.9
(C(6)), 126.3 (C(1)), 149.1 (C(3)), 152.2 (C(4)), 167.9 (CO).
ESI/MS m/z (%): 424 ([M+Na+2]+, 20), 422 ([M+Na]+, 23),
402 ([M+H+2]+, 100), 400 ([M+H]+, 99), 165 (20), 139 (21),
124 (22).
N-(10-Bromodecyl)-3,4,5-trimethoxybenzamide (10).
η = 63%. 1H RMN (CDCl3): δ = 1.26–1.46 (12H, m,
N(CH2)2(CH2)6), 1.55–1.68 (2H, m, NCH2CH2), 1.77–1.90
(2H, m, N(CH2)8CH2), 3.40 (2H, t, J = 6.9Hz, CH2Br), 3.40–
3.48 (2H, m, NCH2), 3.87 (3H, s, OCH3), 3.90 (6H, s, 2 ×
OCH3), 6.13 (1H, s, NH), 6.98 (2H, s, H(2) and H(6)). 13C RMN
(CDCl3): δ = 27.1 (N(CH2)2CH2), 28.3 (N(CH2)7CH2), 28.8
(N(CH2)6CH2), 29.4 (N(CH2)3CH2), 29.4 (N(CH2)4(CH2)2),
29.8 (NCH2CH2), 32.9 (N(CH2)8CH2), 34.1 (CH2Br), 40.4
(NCH2), 56.5 (2 × OCH3), 61.0 (OCH3), 104.5 (C(2) and C(6)),
130.4 (C(1)), 141.0 (C(4)), 153.3 (C(3) and C(5)), 167.4 (CO).
ESI/MS m/z (%): 432 ([M+H+2]+, 17), 430 ([M+H]+, 13), 195
(23), 169 (25), 154 (100).
General procedure used to obtain triphenylphosphonium
salts (11–14)
The appropriate bromo derivative (7–10) (1 mmol) was mixed
with triphenylphosphine (PPh3, 1 mmol) in a round-bottomed
flask and heated to 100◦C for 48 h. The residue was purified
by silica gel flash chromatography using gradient elution (ethyl
acetate:methanol from 9:1 to 6:4). The fractions containing the
desired compound were collected and the solvent was evaporated
to dryness. The reaction was followed by TLC [silica gel, ethyl
acetate:methanol (9:1) and dichloromethane:methanol (9:1)].
The procedure was adapted from the literature (Brown et al.,
2007; Teixeira et al., 2017b).
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(8-(3,4-Dimethoxybenzamido)octyl)triphenylphosphonium
bromide (11). η = 84%. 1H NMR (CDCl3): δ = 1.23–1.43 (6H,
m, NCH2(CH2)3), 1.57–1.71 (6H,m, NCH2CH2(CH2)3(CH2)2),
3.39–3.46 (2H, m, NCH2), 3.68–3.78 (2H, m, CH2P+), 3.87 (3H,
s, OCH3), 3.95 (3H, s, OCH3), 6.87 (1H, d, J = 8.3Hz, H(5)),
7.53 (1H, s, CO), 7.60 – 7.87 (17H, m, H(2), H(6) and PPh3).
13C NMR (CDCl3): δ = 22.5 (d, JCP = 4.7Hz, CH2(CH2)2P+),
22.8 (d, JCP = 49.4Hz, CH2P+), 26.2 (N(CH2)2CH2), 28.0
(N(CH2)4CH2), 28.2 (N(CH2)3CH2), 29.0 (NCH2CH2), 29.8 (d,
JCP = 15.9Hz, CH2CH2P+), 39.9 (NCH2), 56.1 (OCH3), 56.6
(OCH3), 110.5 (C(5)), 111.1 (C(2)), 118.6 (d, JCP = 85.8Hz, 3×
C(1′)), 120.7 (C(6)), 127.6 (C(1)), 130.6 (d, JCP = 12.5Hz, 3 ×
C(3′) and 3 × C(5′)), 133.8 (d, JCP = 10.0Hz, 3 × C(2′) and 3
× C(6′)), 135.1 (d, JCP = 3.0Hz, 3 × C(4′)), 148.8 (C(3)), 151.4
(C(4)), 167.2 (CO). ESI/MS m/z (%): 555 ([M+H-Br]+, 52), 554
([M-Br]+, 100).
(8-(3,4,5-Trimethoxybenzamido)octyl)triphenylphosphonium
bromide (12). η = 87%. 1H NMR (CDCl3): δ = 1.29–1.45 (6H,
m, NCH2(CH2)3), 1.60–1.74 (6H,m, NCH2CH2(CH2)3(CH2)2),
3.43–3.50 (2H, m, NCH2), 3.65–3.74 (2H, m, CH2P+), 3.85
(3H, s, OCH3), 3.95 (6H, s, 2 × OCH3), 7.39 (2H, s, H(2)
and H(6)), 7.66–7.83 (15H, m, PPh3), 8.12 (1H, s, NH). 13C
NMR (CDCl3): δ = 22.4 (d, JCP = 4.6Hz, CH2(CH2)2P+),
22.7 (d, JCP = 49.2Hz, CH2P+), 25.9 (N(CH2)2CH2), 27.6
(N(CH2)4CH2), 27.9 (N(CH2)3CH2), 28.7 (NCH2CH2), 29.6 (d,
JCP = 16.1Hz, CH2CH2P+), 40.0 (NCH2), 57.0 (2 × OCH3),
60.9 (OCH3), 105.3 (C(2) and C(6)), 118.5 (d, JCP = 85.9Hz, 3
× C(1′)), 130.5 (C(1)), 130.6 (d, JCP = 12.5Hz, 3 × C(3′) and
3 × C(5′)), 133.8 (d, JCP = 10.0Hz, 3 × C(2′) and 3 × C(6′)),
135.2 (d, JCP = 3.0Hz, 3 × C(4′)), 140.4 (C(4)), 153.0 (C(3) and
C(5)), 167.2 (CO). ESI/MS m/z (%): 585 ([M+H-Br]+, 48), 584
([M-Br]+, 100).
(10-(3,4-Dimethoxybenzamido)decyl)triphenylphosphonium
bromide (13). η= 82 %. 1HNMR (CDCl3): δ= 1.17 – 1.37 (12H,
m, NCH2(CH2)6), 1.57 – 1.67 (4H, m, NCH2CH2(CH2)6CH2),
3.37 – 3.46 (2H, m, NCH2), 3.71 – 3.83 (2H, m, CH2P+), 3.89
(3H, s, OCH3), 3.93 (3H, s, OCH3), 6.86 (1H, d, J = 8.4Hz,
H(5)), 7.00 (1H, s, NH), 7.48 (1H, d, J = 8.4Hz, H(6)), 7.55
(1H, d, J = 1.8Hz, H(2)), 7.66–7.87 (15H, m, PPh3). 13C
NMR (CDCl3): δ = 22.7 (d, JCP = 4.6Hz, CH2(CH2)2P+),
22.9 (d, JCP = 49.6Hz, CH2P+), 26.7 (N(CH2)2CH2), 28.7
(N(CH2)6CH2), 28.8 (N(CH2)3(CH2)3), 29.4 (NCH2CH2), 30.2
(d, JCP = 15.8Hz, CH2CH2P+), 40.1 (NCH2), 56.1 (OCH3), 56.4
(OCH3), 110.5 (C(5)), 111.0 (C(2)), 118.6 (d, JCP = 85.8Hz, 3
× C(1′)), 120.2 (C(6)), 127.5 (C(1)), 130.6 (d, JCP = 12.5Hz, 3
× C(3′) and 3 × C(5′)), 133.8 (d, JCP = 9.9Hz, 3 × C(2′) and 3
× C(6′)), 135.1 (d, JCP = 2.9Hz, 3 × C(4′)), 148.9 (C(3)), 151.5
(C(4)), 167.2 (CO). ESI/MS m/z (%): 583 ([M+H-Br]+, 38), 582
([M-Br]+, 100).
(10-(3,4,5-Trimethoxybenzamido)decyl)triphenylphosphoni
um bromide (14). η = 92%. 1H NMR (CDCl3):
δ = 1.18–1.38 (12H, m, NCH2(CH2)6), 1.56–1.64 (4H, m,
NCH2CH2(CH2)6CH2), 3.39–3.46 (2H, m, NCH2), 3.68–
3.76 (2H, m, CH2P+), 3.84 (3H, s, OCH3), 3.90 (6H, s, 2
× OCH3), 7.27 (2H, s, H(2) and H(6)), 7.60 (1H, s, NH),
7.65–7.85 (15H, m, PPh3). 13C NMR (CDCl3): δ = 22.6
(d, JCP = 4.3Hz, CH2(CH2)2P+), 22.8 (d, JCP = 49.9Hz,
CH2P+), 26.5 (N(CH2)2CH2), 28.2 (N(CH2)6CH2), 28.5
(N(CH2)3(CH2)3), 29.0 (NCH2CH2), 29.9 (d, JCP = 15.8Hz,
CH2CH2P+), 40.1 (NCH2), 56.7 (2 × OCH3), 60.8 (OCH3),
105.0 (C(2) and C(6)), 118.4 (d, JCP = 85.8Hz, 3 × C(1′)), 130.3
(C(1)), 130.5 (d, JCP = 12.5Hz, 3 × C(3′) and 3 × C(5′)), 133.7
(d, JCP = 9.9Hz, 3× C(2′) and 3× C(6′)), 135.1 (d, JCP = 3.0Hz,
3 × C(4′)), 140.3 (C(4)), 152.9 (C(3) and C(5)), 167.1 (CO).
ESI/MSm/z (%): 613 ([M+H-Br]+, 51), 612 ([M-Br]+, 100).
General procedure used to obtain mitochondriotropic
antioxidants (15–18).
Triphenylphosphonium salt derivative (11–14) (1 mmol) was
dissolved in anhydrous dichloromethane (15mL). The reaction
mixture was stirred under argon and cooled at a temperature
below −70◦C. To this solution, boron tribromide (5–7
mmol, 1M solution in dichloromethane) was added and the
reaction was kept at −70◦C for 10min. After reaching room
temperature, the reaction was continued for 12 h. Thereafter,
the reaction was finished by cautious addition of water
(40mL). After removing the water, the product was dissolved
in methanol and the solvent evaporated. The residue was
purified by cellulose flash chromatography using gradient elution
(dichloromethane:methanol from 9:1 to 6:4). The fractions
containing the desired compound were collected and the solvent
was evaporated to dryness. The reaction was followed by TLC
[silica gel, mobile phase with dichloromethane:methanol (9:1)].
The procedure was adapted from the literature (Milhazes et al.,
2006; Teixeira et al., 2012, 2017a).
(8-(3,4-Dihydroxybenzamido)octyl)triphenylphosphonium
bromide (15). η = 82 %. 1H NMR (DMSO-d6): δ = 1.13
– 1.35 (6H, m, N(CH2)2(CH2)3), 1.36–1.72 (6H, m,
NCH2CH2(CH2)3(CH2)2), 3.09–3.20 (2H, m, NCH2), 3.49–3.63
(2H, m, CH2P+), 6.74 (1H, d, J = 8.2Hz, H(5)), 7.16 (1H, dd,
J = 2.0, 8.2Hz, H(6)), 7.26 (1H, d, J = 2.0Hz, H(2)), 7.71–7.93
(15H, m, PPh3), 8.09 (1H, s, NH). 13C NMR (DMSO-d6):
δ = 20.2 (d, JCP = 49.9Hz, CH2P+), 21.8 (d, JCP = 4.4Hz,
CH2(CH2)2P+), 26.3 (N(CH2)2CH2), 28.0 (N(CH2)4CH2),
28.4 (N(CH2)3CH2), 29.2 (NCH2CH2), 29.7 (d, JCP = 16.5Hz,
CH2CH2P+), 39.0 (NCH2), 114.8 (C(5)), 115.1 (C(2)), 118.6 (d,
JCP = 85.6Hz, 3 × C(1′)), 118.8 (C(6)), 126.0 (C(1)), 130.2 (d,
JCP = 12.4Hz, 3× C(3′) and 3× C(5′)), 133.6 (d, JCP = 10.1Hz,
3 × C(2′), and 3 × C(6′)), 134.9 (d, JCP = 2.8Hz, 3 × C(4′)),
144.7 (C(3)), 148.1 (C(4)), 166.0 (CO). ESI/MS m/z (%): 527
([M+H-Br]+, 55), 526 ([M-Br]+, 100). ESI/HRMS calcd for
C33H37NO3P+ (M+): 526.2506, found 526.2633.
(8-(3,4,5-Trihydroxybenzamido)octyl)triphenylphosphonium
bromide (16). η = 83%. 1H NMR (DMSO-d6): δ = 1.13
– 1.32 (6H, m, N(CH2)2(CH2)3), 1.36 – 1.60 (6H, m,
NCH2CH2(CH2)3(CH2)2), 3.06–3.20 (2H, m, NCH2), 3.39–3.66
(5H, m, CH2P+ and 3 × OH), 6.80 (2H, s, H(2) and H(6)),
7.71–7.93 (15H, m, PPh3), 7.99 (1H, s, NH). 13C NMR (DMSO-
d6): δ = 20.1 (d, JCP = 49.3Hz, CH2P+), 21.7 (d, JCP = 4.2Hz,
CH2(CH2)2P+), 26.3 (N(CH2)2CH2), 28.0 (N(CH2)4CH2),
28.4 (N(CH2)3CH2), 29.1 (NCH2CH2), 29.7 (d, JCP = 16.4Hz,
CH2CH2P+), 38.9 (NCH2), 106.7 (C(2) and C(6)), 118.6 (d,
JCP = 85.6Hz, 3 × C(1′)), 125.2 (C(1)), 130.2 (d, JCP = 12.4Hz,
3 × C(3′) and 3 × C(5′)), 133.6 (d, JCP = 10.1Hz, 3 × C(2′) and
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3× C(6′)), 134.9 (d, JCP = 2.8Hz, 3× C(4′)), 136.0 (C(4)), 145.3
(C(3) and C(5)), 166.2 (CO). ESI/MSm/z (%): 543 ([M+H-Br]+,
100), 542 ([M-Br]+, 59). ESI/HRMS calcd for C33H37NO4P+
(M+): 542.2455, found 542.2412.
(10-(3,4-Dihydroxybenzamido)decyl)triphenylphosphonium
bromide (17). η = 69%. 1H NMR (DMSO-d6): δ = 1.11–
1.30 (10H, m, N(CH2)2(CH2)5), 1.36–1.61 (6H, m,
NCH2CH2(CH2)5(CH2)2), 3.10–3.25 (2H, m, NCH2), 3.46–3.62
(4H, m, CH2P+ and 2 × OH), 6.73 (1H, d, J = 8.2Hz, H(5)),
7.16 (1H, dd, J = 2.1, 8.2Hz, H(6)), 7.25 (1H, d, J = 2.1Hz,
H(2)), 7.74–7.91 (15H, m, PPh3), 8.07 (1H, t, J = 5.6Hz, NH).
13C NMR (DMSO-d6): δ = 20.1 (d, JCP = 50.2Hz, CH2P+),
21.7 (d, JCP = 4.7Hz, CH2(CH2)2P+), 26.5 (N(CH2)2CH2),
28.0 (N(CH2)6CH2), 28.6 (N(CH2)3CH2), 28.7 (N(CH2)5CH2),
28.8 (N(CH2)4CH2), 29.2 (NCH2CH2), 29.8 (d, JCP = 16.4Hz,
CH2CH2P+), 39.0 (NCH2), 114.7 (C(5)), 115.0 (C(2)), 118.6 (d,
JCP = 85.6Hz, 3 × C(1′)), 118.8 (C(6)), 126.0 (C(1)), 130.2 (d,
JCP = 12.4Hz, 3× C(3′) and 3× C(5′)), 133.6 (d, JCP = 10.1Hz,
3 × C(2′) and 3 × C(6′)), 134.9 (d, JCP = 3.0Hz, 3 × C(4′)),
144.7 (C(3)), 148.1 (C(4)), 165.9 (CO). ESI/MS m/z (%): 555
([M+H-Br]+, 58), 554 ([M-Br]+, 100). ESI/HRMS calcd for
C35H41NO3P+ (M+): 554.2819, found 554.2821.
(10-(3,4,5-Trihydroxybenzamido)decyl)triphenylphosphoni
um bromide (18). η = 89%. 1H NMR (DMSO-d6):
δ = 1.02–1.30 (10H, m, N(CH2)2(CH2)5), 1.34–1.59 (6H,
m, NCH2CH2(CH2)5(CH2)2), 3.06–3.20 (2H, m, NCH2), 3.46–
3.64 (2H, m, CH2P+), 6.80 (2H, s, H(2) and H(6)), 7.69–7.93
(15H, m, PPh3), 8.00 (1H, s, NH). 13C NMR (DMSO-d6):
δ = 20.2 (d, JCP = 50.1Hz, CH2P+), 21.7 (d, JCP = 4.2Hz,
CH2(CH2)2P+), 26.4 (N(CH2)2CH2), 28.0 (N(CH2)6CH2),
28.6 (N(CH2)3CH2), 28.7 (N(CH2)5CH2), 28.8 (N(CH2)4CH2),
29.2 (NCH2CH2), 29.7 (d, JCP = 16.4Hz, CH2CH2P+), 39.0
(NCH2), 106.7 (C(2) and C(6)), 118.6 (d, JCP = 85.6Hz, 3 ×
C(1′)), 125.2 (C(1)), 130.2 (d, JCP = 12.4Hz, 3 × C(3′) and 3
× C(5′)), 133.6 (d, JCP = 10.1Hz, 3 × C(2′) and 3 × C(6′)),
134.9 (d, JCP = 2.8Hz, 3 × C(4′)), 136.0 (C(4)), 14537 (C(3)
and C(5)), 166.2 (CO). ESI/MSm/z (%): 571 ([M+H-Br]+, 100),
570 ([M-Br]+, 13). ESI/HRMS calcd for C35H41NO4P+ (M+):
570.2768, found 570.2885.
Evaluation of Radical Scavenging Activity
The radical scavenging activity of compounds AntiOxBEN1,
AntiOxBEN2, and 15–18 was evaluated using the total
antioxidant capacity spectrophotometric assays based on the
DPPH• (2,2′-diphenyl-1-picrylhydrazyl) and ABTS•+ (2,2′-
azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)) radicals.
DPPH• radical assay
DPPH• radical scavenging activity was evaluated as previously
described (Teixeira et al., 2017b). The IC50 values were
determined in triplicate from the dose-response inhibition curves
and are expressed as mean± standard deviation (SD).
ABTS•+ radical cation assay
ABTS•+ scavenging activity was evaluated as previously
described (Teixeira et al., 2017b). The IC50 values were
determined in triplicate from the dose-response inhibition curves
and are expressed as mean± standard deviation (SD).
Evaluation of Redox Properties
Voltammetric studies were performed using an Autolab
PGSTAT12 potentiostat/galvanostat (Metrohm Autolab,
Netherland) and a one-compartment glass electrochemical cell.
Voltammetric curves were recorded at room temperature using
a three-electrode system, according the conditions previously
described (Teixeira et al., 2017b).
Pharmacology
Reagents and General Conditions
Acetylcholinesterase (AChE) from Electrophorus electricus
(electric eel), butyrylcholinesterase (BChE) and acetylthiocholine
iodide (ATCI), butyrylthiocholine iodide (BTCI), 5,5′-dithiobis-
(2-nitrobenzoate) (DTNB), (4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium (MTT) bromide and Dulbecco’s modified
Eagle’s medium (DMEM) with 4.5 g/L glucose were obtained
from Sigma-Aldrich Química S. A. Reagents used in cell culture,
including nonessential amino acids (NEAA), heat inactivated
fetal bovine serum (FBS), 0.05% trypsin/1mM EDTA, antibiotic
(10000 U/mL penicillin, 10,000µg/mL streptomycin) and Hank’s
balanced salt solution (HBSS) were purchased from Gibco
Laboratories. Dimethylsulfoxide (DMSO-d6), absolute ethanol
and acetic acid were obtained from Merck. All reagents were of
analytical grade or of the highest grade available.
Evaluation of Acetyl and Butyrylcholinesterase
Inhibitory Activity
The AChE and BChE inhibitory activities of the compounds
under study were evaluated following Ellman’s method (Ellman
et al., 1961; Di Giovanni et al., 2008). The solutions of enzyme
(AChE, 0.5 U/mL; BChE, 0.25 U/mL) and DTNB (2.14mM)
were prepared in sodium phosphate buffer. ATCI (8.04mM)
or BTCI (5.12mM) solutions were prepared in deionised water
(conductivity < 0.1 µS·cm−1).
Briefly, 100 µL of sodium phosphate buffer, 40 µL of DTNB,
20 µL of the test compounds/standard inhibitors and 20 µL
of AChE or BChE were incubated for 5min at 30◦C in a 96-
well microplate (BRANDplates, pureGradeTM, BRAND GMBH,
Wertheim, Germany). After that, 20 µL of ATCI or BTCI was
added, respectively. The absorbance values were registered every
minute for 5 more minutes at 30◦C (at 412 nm). A control using
20 µL of sodium phosphate buffer instead of compound solution
was also performed. The IC50 values were determined in triplicate
from the dose-response inhibition curves and are expressed as
mean± standard deviation (SD).
Evaluation of enzyme (AChE and BChE) kinetics.
To determine the steady-state kinetic parameters (Km, Michaelis
constant and Vmax, maximum reaction rate) of AChE and BChE,
their enzymatic activities were evaluated (under the experimental
conditions described above) in the presence of different ATCI or
BTCI concentrations. Under our experimental conditions, AChE
displayed a Km of 117.3 ± 29.7µM and a Vmax of 0.27 ± 0.03
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1A/min whereas BChE showed a Km of 244.4 ± 15.0µM and a
Vmax of 0.2772± 0.0007 1A/min (determined in triplicate).
Evaluation of AChE- and BChE-inhibitor kinetics
To evaluate the mechanism of AChE and BChE inhibition
of the most promising compounds substrate-dependent kinetic
experiments were performed. The catalytic rates of AChE were
measured at five different concentrations of ATCI substrate
(50–800µM) and BChE at four different concentrations of
BTCI substrate (62.5–500µM) in the absence or presence
of the selected inhibitors (compounds 18 and AntiOxBEN1)
and standard inhibitor (donepezil, at concentrations between
12.5 nM and 40.0µM). The results are presented as double
reciprocal Lineweaver-Burk plots (1/V vs. 1/[S]). The kinetic
data, namely Km and Vmax, were acquired employing Michaelis-
Menten equation. The Ki values were estimated using Dixon
plots, by replotting the slope of each Lineweaver-Burk plot vs.
the inhibitor concentration. In the Dixon plots, the Ki value was
obtained from the x-axis intercept (–Ki). The enzymatic reactions
and measurements were performed using the same AChE
and BChE assay conditions as described above (determined
in triplicate). Linear regression analysis was performed using
GraphPad Prism 5.0 (GraphPad Software, Inc.).
Evaluation of Cytotoxicity/Antioxidant Outline in
Cell-Based Assays
Cell Culture
SH-SY5Y (ATCC, Manassas, VA, USA), a neuroblastoma cell
line, was routinely cultured in 75-cm2 flasks (Corning Costar,
Corning, NY, USA) using DMEM with 4.5 g/L glucose,
supplemented with 10% heat-inactivated FBS (v/v), 1% NEAA
(v/v), 100 U/mL penicillin, and 100µg/mL streptomycin. The
cells used for all the experiments were taken between the 37th and
45th passages, to avoid phenotypic changes. For all experiments,
undifferentiated SH-SY5Y cells were seeded onto 96-well plates
(8,000 cells/well) in cell culture medium supplemented with 0.1%
of retinoic acid for 3 days at 37◦C for differentiated cells. Three
days after seeding, the medium of cells was changed, adding
cell culture medium with 0.1% of TPA for more 3 days before
treatment.
Human hepatocellular carcinoma cells (HepG2, ECACC, UK)
were also used in this study. Cells were cultured in low-
glucose medium (5mM) composed by Dulbecco’s modified
Eagle’s medium (DMEM, D5030) supplemented with sodium
pyruvate (0.11 g/L), sodium bicarbonate (3.7 g/L), HEPES (1.19
g/L), 6mM glutamine and 10% fetal bovine serum (FBS) and
1% of antibiotic penicillin-streptomycin 100 × solution. HepG2
(2.5 × 104 cells/well) cells were seeded in a 96-well plate and
proliferate for 24 h before treatment.
All cells were maintained and cultured at 37◦C in a humidified
atmosphere of 95% air/5% CO2 and passaged weekly by
trypsinization (0.05% trypsin/1mM EDTA) when reaching 70–
80% confluence.
Evaluation of Cytotoxicity
The cytotoxicity profile of the compounds under study was
evaluated in differentiated SH-SY5Y cells (8,000 cells/well),
according the differentiation protocol previously described, and
in HepG2 cells (2.5 × 104 cells/well), seeded into 96-well plates.
Then, the cells were exposed to increased concentrations of the
test compounds (1, 10 and 50µM) in cell culture medium for
24 h in SH-SY5Y cells or 48 h in HepG2 cells and the cytotoxicity
was evaluated through measuring changes in cellular metabolic
activity using theMTT or resazurin reduction assays, respectively
(Silva et al., 2016). In both assays, the reduction of MTT
tetrazolium salt or resazurin to MTT formazan or resorufin,
respectively, by cellular dehydrogenases present in viable cells,
gives insights on cell metabolic activity.
For the MTT assay, the cell culture medium was removed
after the incubation time, followed by the addition of fresh cell
culture medium containing 0.5 mg/mL MTT and incubation for
30min. After this incubation period, the cell culture medium was
removed, and the formed formazan crystals dissolved in DMSO.
The absorbance was measured at 550 nm in a multi-well plate
reader (BioTek Instruments, Vermont, USA). The percentage of
MTT reduction relative to that of the control cells was used as the
cytotoxicity measure [MTT reduction (% of control)] as means±
SEM of four independent experiments.
Regarding the resazurin reduction assay, after the incubation
time, the medium was replaced by fresh medium containing
resazurin (10µg/mL) prepared in sterile PBS (1X) and left to
react for 1 h. The fluorescent signal was monitored using a
540 nm excitation wavelength and 590 nm emission wavelength
in a Cytation 3 reader (BioTek Instruments Inc., USA). The
percentage of resazurin reduction relative to that of the control
cells was used as the cytotoxicitymeasure [resazurin reduction (%
of control)] as means± SEM of four independent experiments.
Control experiments were performed for both viability
endpoints by adding vehicle (medium with 0.1% DMSO) instead
of the compound solution.
Evaluation of neuroprotective activity
The antioxidant efficiency of the new HBAc derivatives was
evaluated in the presence of Aβ1–42 peptide. The synthetic
peptide Aβ1–42, corresponding to neurotoxic amino acid
residues of the human amyloid-beta protein (Aβ), was dissolved
in sterile water in order to facilitate peptide solubilization at
a concentration of 1 g/L (221.5µM). Aβ1–42 aliquots were
then stored at −20◦C until use (enriched oligomeric Aβ1–42
preparation).
Undifferentiated SH-SY5Y cells were seeded onto 96-well
plates (8000 cells/well) and differentiated as previously described.
The cells were incubated with AntiOxBEN1, AntiOxBEN2 and
15–18 (10µM) for 24 h. Then, oligomeric Aβ1–42 (25 µmol/L)
was added to the culture medium of the SH-SY5Y cells for
more 48 h. After incubation time, cellular metabolic activity was
determined using the resazurin reduction assay as previously
described.
Data Analysis
For the radical scavenging and enzymatic inhibition studies, the
compounds were initially screened at 50µM. For the most potent
compounds, dose-response curves were plotted and IC50 values
were estimated by non-linear analysis. For the cytotoxicity assays,
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SCHEME 1 | Synthetic strategy followed to obtain derivatives 15–18 from benzoic acids 1–2. Reagents and conditions: a. POCl3, NH2(CH2)7CH2OH or
NH2(CH2)9CH2OH, DIPEA, DCM, r.t., 1–2 h; b. C2Br2Cl4, diphos, THF, r.t., 20 h; c. PPh3, 100
◦C, 48 h; d. BBr3, anhydrous DCM, −70
◦C to r.t., 12 h.
MTT and resazurin reduction were calculated for each treatment
as the % of control untreated cells and plotted in column graphs.
Data were analyzed in GraphPad Prism 5.0 software
(GraphPad Software, Inc.), with all results being expressed as
means ± SEM for the number of experiments indicated. In
data analysis, student’s t-test was used for comparison of two
means, and one-way ANOVA with Dunnet multiple comparison
post-test was used to compare more than two groups with one
independent variable. Significance was accepted with ∗P < 0.05,
∗∗P < 0.01, ∗∗∗P < 0.0005, ∗∗∗∗P < 0.0001.
Molecular Docking Studies
Docking simulations were performed with the Schrödinger 2017
package (Schrödinger suite 2017-2, 2017). The crystal structure
of the human BChE was downloaded from the PDB (code:
4B0O) (Wandhammer et al., 2013) and pre-processed with the
Protein Preparation Workflow (Schrödinger suite 2017-2, 2017).
This procedure included steps such as addition of cap termini,
optimization of hydrogens, protonation states of residues and H-
bond network optimization. Only one water molecule stabilized
through two hydrogen bonds with the protein (residues Asp70
and Ser79) was retained in the pocket for the simulations.
Before docking, a receptor grid was generated using the co-
crystallized ligand as a center (box length = 20 Å, van der
Waals scaling factor= 1.0, partial charge cut-off= 0.25). Ligands
were docked to the protein with Glide SP (Standard Precision)
(Schrödinger suite 2017-2, 2017). The best pose according to
the parameter “Emodel energy” was retained and considered
representative of the calculation. The docking protocol was
validated measuring the RMSD (root mean square deviation)
between 5 co-crystallized ligands downloaded from the PDB and
their calculated poses extracted from docking (RMSD values:




The novel HBAc derivatives were obtained following a
four-step synthetic strategy depicted in Scheme 1, using
3,4-dimethoxybenzoic acid (1) and 3,4,5-trimethoxybenzoic
acid (2) as starting compounds. The first synthetic step (a)
was an amidation reaction of the acids 1 and 2: phosphorus
oxychloride was used as coupling agent for the introduction
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TABLE 1 | Total antioxidant capacity and ChEs inhibitory activity (IC50) data of compounds AntiOxBEN1, AntiOxBEN2, 15–18 and donepezil.
Compound Structure IC50 (µM ± SD) IC50 (nM ± SD) SI Ep (mV)
DPPH• ABTS•+ AChE BChE
AntiOxBEN1 31.0 ± 0.8* 20.7 ± 0.8* >50 85 ± 5 > 588 219*
AntiOxBEN2 14.0 ± 0.3* 6.5 ± 0.5* 40.5 ± 7.0 474 ± 17 86 115*
15 31.2 ± 0.9 23.5 ± 1.3 11.2 ± 0.8 106 ± 5 106 216
16 16.8 ± 1.6 6.8 ± 0.6 15.7 ± 0.9 255 ± 9 62 121
17 31.0 ± 0.6 19.4 ± 1.0 7.7 ± 0.4 195 ± 20 41 210
18 10.2 ± 1.1 7.4 ± 0.5 7.2 ± 0.5 553 ± 22 13 114
Donepezil n.d. n.d. 0.025 ± 0.001 2200 ± 200 0.011 n.d.
n.d.: not determined.
*Data from Teixeira et al. (2017a).
SI: BChE selectivity index = IC50(AChE)/IC50(BChE).
of the 8-aminooctan-1-ol and 10-aminodecan-1-ol spacers
leading to derivatives 3–6. Subsequently, these derivatives
were treated with 1,2-dibromotetrachloroethane and 1,2-
bis(diphenylphosphine)ethane (diphos) (step b), leading to
halogenated derivatives 7–10. The triphenylphosphonium salts
11–14 were then obtained by a reaction with triphenylphosphine
in step c, followed by a final O-demethylation process (step
d) to afford derivatives 15–18. Using this synthetic strategy,
four derivatives were obtained, bearing different spacer
lengths and number of phenolic functions at the aromatic
ring.
The structural identity was confirmed by nuclear magnetic
resonance (NMR) spectroscopy (1H NMR, 13C NMR and
DEPT135) and electron impact (EI/MS) or electrospray
ionization mass spectra (ESI/MS).
Evaluation of Radical Scavenging Activity
Total antioxidant capacity assays (DPPH• and ABTS•+) were
used to evaluate the antioxidant capacity of compounds 15–18. In
these assays, the ability of an antioxidant to transfer a hydrogen
atom or an electron to a stable free radical is related with a
radical absorbance decrease and, consequently, compounds with
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TABLE 2 | Drug-like properties of compounds AntiOxBEN1, AntiOxBEN2, 15-18 and donepezil.
Compound MWa clog Pa tPSA (Å2)a HBAa HBDa nrotba log BBa
AntiOxBEN1 498.6 6.49 69.56 4 3 12 −0.588
AntiOxBEN2 514.6 5.81 89.79 5 4 12 −0.665
15 526.6 6.93 69.56 4 3 14 −0.594
16 542.6 6.31 89.79 5 4 14 −0.675
17 554.7 7.32 69.56 4 3 16 −0.600
18 570.7 6.74 89.79 5 4 16 −0.685
Donepezil 379.5 3.54 38.77 4 0 6 0.790
CNS+ drugs (Pajouhesh and Lenz, 2005; Hitchcock and Pennington, 2006; Fong,
2015; Rankovic, 2015; Nikolic et al., 2016)
<450 <5 <60–70 <7 <3 <8 ≥−1
aProperties calculated using StarDrop software. MW, molecular weight; clogP: logarithm of the octanol-water partition coefficient; tPSA, topological polar surface area; HBA, number
of hydrogen acceptors; HBD, number of hydrogen donors; nrotb, number of rotatable bonds; log BB, logarithm of the ratio of the concentration of a drug in the brain and in the blood.
a higher antioxidant activity display a lower IC50 value. The
data related with AntiOxBEN1 and AntiOxBEN2 (Figure 1)
was previously published, and included for comparative analysis
(Teixeira et al., 2017b).
Results showed that pyrogallol derivatives AntiOxBEN2,
16, 18 displayed a superior antioxidant activity over the
corresponding catechols AntiOxBEN1, 15, 17 (Table 1).
Although the length of the carbon alkyl chain did not alter
the antioxidant capacity of the synthesized HBAc derivatives,
the presence of the TPP+ moiety decreased their antioxidant
capacity, a fact that may be related with stereochemical
hindrances.
Evaluation of Redox Properties
During the last decade, electrochemical methods have attracted
a great deal of attention given their enormous potential for the
assessment of antioxidant capacity. Since antioxidants can act
as reducing agents, they are electrochemically active and can
be measured using electrochemical techniques (Teixeira et al.,
2017a,b; Apak et al., 2018). Moreover, these methods provide a
fast, simple and a low-cost alternative to measure antioxidant
compounds and monitor their antioxidant capacity in biological
and food samples (Teixeira et al., 2017a,b; Apak et al., 2018).
The oxidative profile of compounds 15–18 was evaluated
at physiological pH 7.4, by differential pulse and cyclic
voltammetry, using a glassy carbon working electrode. The
DPV voltammograms obtained for catechol derivatives (15
and 17) showed the occurrence of only one anodic peak at
an oxidation potential (Ep) between + 210 and + 216mV
(Table 1) at physiological pH. Cyclic voltammograms were
also recorded for these derivatives and the data obtained was
characteristic of an electrochemical reversible reaction showing
only one anodic peak and one cathodic peak on the reverse
scan. DPV of the compounds containing a pyrogallol moiety
(16 and 18) were also obtained and showed the presence of
two overlapped anodic waves occurring at an Ep ranging from
+ 114 to + 121mV, at physiological pH (Table 1). The cyclic
voltammograms also showed the presence of two overlapped
peaks with no reduction peak on the cathodic sweep, indicating
that the oxidative process may correspond to an irreversible
reaction.
The results were in accordance with the data previously
obtained forAntiOxBEN1,AntiOxBEN2 and their parent HBAc
(PA and GA) (Teixeira et al., 2017b) reinforcing our believe
that the redox potential of these mitochondriotropic antioxidants
is mainly associated with the number of hydroxyl substituents
on the aromatic pattern. Furthermore, the data showed that
the oxidation potentials observed are closely related to the
antioxidant activity evaluated by total antioxidant assays. In fact,
pyrogallol derivatives that presented lower oxidation potentials,
exhibited higher antioxidant activities when compared with
compounds bearing a catechol group (Table 1). On the other
hand, the results showed that the increase of the length of alkyl
spacer does not significantly influence the redox properties of the
compounds, under the experimental conditions used.
Evaluation of AChE/BChE Inhibitory
Activities
The inhibitory activity of the compounds AntiOxBEN1,
AntiOxBEN2, and 15–18 on AChE and BChE was evaluated
by the Ellman’s method (Ellman et al., 1961; Di Giovanni
et al., 2008). ATCI and BTCI were used as substrates for AChE
or BChE, respectively, generating thiocholine and acetate or
butyrate. In this assay, the released thiocholine reacts with the ion
DTNB to produce the anion 5-thio-2-nitrobenzoate (TNB2−),
which was determined by UV/Vis spectroscopy (Ellman et al.,
1961; Di Giovanni et al., 2008), enabling the determination
of the inhibitory potency (IC50 values) after incubation
with the test compounds (Table 1). Donepezil (Table 1) a
selective and reversible AChE inhibitor drug approved by
FDA for AD treatment (Colović et al., 2013) was used as
standard.
With the exception of AntiOxBEN1, which did not have
any effect on AChE at 50µM, all derivatives effectively
inhibited both AChE and BChE under the experimental
conditions. Concerning AChE, derivatives presenting the longer
spacers showed improved binding to the enzyme’s active
site. In fact, compounds 17 and 18, with a ten-carbon
chain, showed greater potency (IC50 = 7.7 and 7.2µM,
respectively) than AntiOxBEN1, AntiOxBEN2 (IC50 = > 50
and 40.5µM, respectively) and derivatives 15–16 (IC50 = 11.2
and 15.7µM, respectively) (Table 1). The compounds with
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FIGURE 2 | Cytotoxicity profile of compounds (A) AntiOxBEN1, (B) AntiOxBEN2, (C) 15, (D) 16, (E) 17, and (F) 18 measured by changes in cellular metabolic
activity on human neurablastoma SH-SY5Y and human hepatocarcinoma HepG2 cells after 24 or 48 h treatment time, respectively, at three different concentrations
(1, 10, and 50µM). Cellular viability was evaluated using two methods: MTT in differentiated SH-SY5Y and resazurin reduction assays in HepG2 cells. Untreated cells
were used as control. Data are means ± SEM of three independent experiments and the results are expressed as percentage of control (control = 100%), which
represents the cell density without any treatment in the respective time point. Significance was accepted with *P < 0.05, **P < 0.01, ***P < 0.0005 vs. control.
shorter alkyl spacers (AntiOxBEN1, 15 and 16) showed higher
inhibitory potency toward BChE (IC50 = 85, 106 and 255 nM,
respectively).
Catechol derivatives AntiOxBEN1, 15 and 17 (IC50 = 85–
190 nM) showed better performance than pyrogallols
AntiOxBEN2, 16 and 18 (IC50 = 255–550 nM).
As expected donepezil showed a higher potency for AChE
than BChE (IC50 = 25± 1 nM and 2.2± 0.2µM, respectively).
The BChE selectivity index (SI) calculated from the ratio of the
IC50 values of AChE and BChE showed that the most selective
compounds were AntiOxBEN1 and 15 (over 588- and 106-
fold more active toward BChE than AChE, respectively). Thus,
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the modifications performed in PA significantly increased their
inhibitory effect in BChE.
Evaluation of Drug-Like Properties
The drug-like properties were determined for compounds
AntiOxBEN1, AntiOxBEN2, 15–18, donepezil and precursors
PA and GA. The calculated physicochemical parameters
included: molecular weight (MW), partition coefficient (clog P),
topological polar surface area (tPSA in Å2), number of hydrogen
acceptors (HBA), number of hydrogen donors (HBD), number
of rotatable bonds (nrotb) and blood (plasma)-brain partitioning
(logBB) (Table 2). Along theoretical calculations of clogP, it was
observed that the programs used do not include ionic compounds
(as mitochondriotropic salts). Therefore, all the calculations were
done with the neutral molecule, resulting in higher partition
coefficients than expected. Due to the high volume of the aliphatic
TPP+ moiety, the MW and clogP values overcome the upper
limit established by the “Rule of 5” (MW ≤ 500 g/mol and
clogP ≤ 5) (Lipinski et al., 2001). However, this problem can be
counterbalanced by its therapeutic profile, i.e., the ability of TPP+
moiety to rapidly cross phospholipid bilayers and, consequently,
accumulate in mitochondria (Murphy and Smith, 2007).
The values of HBD and HBA obtained were in accordance
with the general drug-likeness requirements of the Linpinski’s
“Rule of 5” (with HBD< 5 and HBA< 10) (Lipinski et al., 2001).
Another key measurement is the prediction of blood-brain
barrier (BBB) permeability, determined by the logBB, which is
the ratio of the steady-state concentrations of the drug in the
brain and in the blood. Compounds with logBB < −1 are poorly
distributed to the brain and are unlikely to function as effective
central nervous system (CNS) drugs (Clark, 1999). Compounds
AntiOxBEN1, AntiOxBEN2, and 15–18 displayed logBB ≥ −1,
pointing toward potential BBB permeability.
As expected, the values obtained for donepezil were all in
accordance with the general drug-likeness requirements of the
Linpinski’s “Rule of 5.”
Evaluation of Cytotoxicity Profile
The cytotoxicity profile of compounds AntiOxBEN1,
AntiOxBEN2, and 15–18 was evaluated by the determination
of the cellular metabolic activity in differentiated human
neuroblastoma cells (SH-SY5Y) and human hepatocarcinoma
cells (HepG2), after a 24 or 48 h incubation period, respectively,
at three different concentrations (1, 10, and 50µM) (Figure 2).
Both cell lines are often used in the preclinical safety assessment
of drug candidates, being the SH-SY5Y cells of particular interest
concerning the drug candidates for CNS (Lin and Will, 2012).
Metabolically active cells reduce MTT and resazurin to formazan
and resorufin, respectively, which can be spectrophotometrically
quantified, providing an indirect measure of cell viability
(Lobner, 2000). Although the AntiOxBEN1, AntiOxBEN2
cytotoxicity on HepG2 has been previously described (Teixeira
et al., 2017b), they were re-evaluated for comparative analysis.
In general, the cytotoxicity profile of all compounds followed
the same trend independently of the cell line used for
safety assessment. Moreover, the results clearly showed that
compounds AntiOxBEN2, 16 and 18, containing the pyrogallol
FIGURE 3 | Neuroprotective effects of compounds (A) AntiOxBEN1, 15 and
17 and (B) AntiOxBEN2, 16 and 18 in human neuroblastoma SH-SY5Y cells
against Aβ1–42 peptide-induced cytotoxicity measured by changes in cellular
metabolic activity. Cells were pre-treated with mitochondriotropic antioxidants
(10µM) for 24 h before treatment with Aβ1–42 peptide (25µM) for 48 h more.
The comparisons were performed by using one-way ANOVA between the
control (Aβ1–42 peptide) vs. preparation where antioxidants AntiOxBEN1,
AntiOxBEN2 and 15–18 were pre-incubated. Data are means ± SEM of three
independent experiments and the results are expressed as percentage of
control (control = 100 %), which represents the cell density without any
treatment in the respective time point. Significance was accepted with
**P < 0.01 vs. control.
moiety, did not alter cellular metabolic activity for all tested
concentrations, presenting a larger safety margin toward SH-
SY5Y and HepG2 cells. Interestingly, compound 18 slightly
increased SH-SY5Y (1 and 10µM) and HepG2 (10 and 50µM)
metabolic activity.
On the other hand, compounds with the catechol moiety
(AntiOxBEN1, 15 and 17) presented dose-dependent toxicity in
both SH-SY5Y and HepG2 cells. Compounds 15 and 17 were
the most cytotoxic compounds, showing that longer spacers
increased the toxicity effects of catechol-derived compounds.
From the cytotoxic profile on both SH-SY5Y and HepG2 cells,
it can be concluded that compounds containing the catechol
moiety, with exception of AntiOxBEN1, exhibited a higher
toxicity than compounds with the pyrogallol moiety.
Evaluation of Neuroprotective Properties
Aβ aggregation, the pathological hallmark of AD, is the most
targeted biomarker in drug discovery and development for AD.
As ChEs colocalize with the amyloid and may contribute to the
generation of amyloid proteins, it was found relevant to check
the neuroprotective properties of compounds under study. The
experiments were performed in SH-SY5Y cells using Aβ1–42, a
synthetic toxic fragment of the amyloid protein (Resende et al.,
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FIGURE 4 | Kinetic studies on the mechanism of AChE inhibition by compounds and (A) 18, and (B) donepezil. The effect of the inhibitors on the enzyme was
determined from the double reciprocal plot of 1/rate (1/V) vs. 1/substrate concentration in presence of varying concentrations of the inhibitors. The Ki values were
calculated by the intersection of the curves obtained by plotting 1/V vs. the inhibitor concentration for each substrate concentration (Dixon plots insets on the top right).
FIGURE 5 | Kinetic studies on the mechanism of BChE inhibition by (A) AntiOxBEN1 and (B) donepezil. The effect of the inhibitors on the enzyme was determined
from the double reciprocal plot of 1/rate (1/V) vs. 1/substrate concentration in presence of varying concentrations of the inhibitors. The Ki values were calculated by
the intersection of the curves obtained by plotting 1/V vs. the inhibitor concentration for each substrate concentration (Dixon plots insets on the top right).
2008), as oxidative insult. Consequently, SH-SY5Y cells were
treated with Aβ1–42 peptide (25µM) for 48 h and then the cell
metabolic activity was measured by colorimetric resazurin assay,
which significantly decrease the cell viability of about 28% when
compared to control.
In general, pre-treatment of SH-SY5Y cells with compounds
AntiOxBEN1, AntiOxBEN2 and 15–18 (10µM, Figure 3)
for 24 h reduced Aβ1–42 peptide-induced cytotoxicity, being
those effects more evident for compounds 17 (presenting
a catechol moiety and a longer spacer) and AntiOxBEN2
and 16 (with a pyrogallol moiety and shorter alkyl spacers)
(Figure 3). Several mechanisms, such as inhibition of
mitochondrial Ca2+ overload and of caspase cascade, may
underlie HBAc derivatives-induced neuroprotection against
Aβ neurotoxicity, which will be the subject of a follow-up
study.
Evaluation of Enzyme-Inhibition
Mechanism of AntiOxBEN1 and 18
In order to understand the AChE and BChE inhibitory
mechanism of the most promising ChE inhibitors, kinetic
experiments were performed. For this purpose, the enzymatic
inhibition kinetics was measured, using different substrate
concentrations in absence or presence of the selected compounds
at different concentrations, including the standard inhibitor
donepezil (Figures 4, 5). Graphical analysis of the reciprocal
Lineweaver–Burk plots was used to determine Michaelis-Menten
reaction kinetic parameters (Km and Vmax).
AChE Kinetics
Concerning compound 18 (Figure 4A), results showed thatVmax
decreased while Km remained unchanged. The same kinetic
behavior was observed for donepezil (Figure 4B) (Sugimoto
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TABLE 3 | Emodel and SP scoring values for co-crystallized ligands and our set of
derivatives.












*Co-crystallized ligands. Units, kcal/mol.
et al., 2002; Pohanka, 2014). The Lineweaver-Burk plots obtained
for compound 18 and donepezil displayed a series of converging
lines on the same point of the x-axis (1/[S]), profiling a non-
competitive inhibition mechanism (Figure 4).
From the Dixon plots, obtained from the replots of the
slopes of the Lineweaver–Burk plots vs. inhibitor concentrations
(Figure 4, upper right corners), the AChE inhibition binding
affinities, determined as inhibition constants (Ki), were
calculated. Compound 18 (Figure 4A) displayed a Ki value
of 6.6µM, which correlated well with its experimental IC50
(7.2µM). The similar IC50 and Ki values confirmed its non-
competitive inhibition profile. The kinetic inhibition profile
is similar to donepezil (Ki = 16.4 nM and IC50 = 24.6 nM,
Figure 4B).
BChE Kinetics
The kinetics determined for AntiOxBEN1 (the most selective
compound) showed that the Vmax decreased while Km remained
unchanged (Figure 5A). The same profile was obtained for
donepezil (Figure 5B). The Lineweaver-Burk plots obtained for
AntiOxBEN1 and donepezil (Figures 5A,B) displayed a series of
converging lines on the same point of the x-axis (1/[S]), profiling
a non-competitive inhibition mechanism.
From the Dixon plots, obtained from the replots of the slopes
of the Lineweaver–Burk plots vs. inhibitor concentrations (upper
right corner), the BChE inhibition binding affinities, determined
as inhibition constants (Ki), were calculated. AntiOxBEN1
(Figure 5A) displayed Ki value of 29.5 nM and IC50 = 85 nM.
This compound displayed IC50 and Ki values different but in the
same range, with an acceptable correlation between its respective
values. Donepezil showed a similar kinetic behavior (Ki= 1.6µM
and IC50 = 2.2µM, Figure 5B).
Molecular Docking Studies
Molecular docking simulations of the best BChE inhibitors of
the series were performed to study the main ligand-protein
interactions. In the modeling, the crystallized human protein
structure 4B0O (PDB code) was used. (Wandhammer et al.,
2013). The ligands were docked with Glide SPmode (Schrödinger
suite 2017-2, 2017) and the best pose according to the energetic
parameter Emodel was retained for graphical purposes (seeTable 3
with SP and Emodel values). The geometrical quality of the
docking protocol was evaluated measuring the RMSD between
co-crystallized ligands and theoretical poses extracted from
docking (see Methods).
The RMSD values were lower than 2.5 Å for 3 out of 5
co-crystallized ligands showing the ability of the docking to
reproduce some co-crystallized structures. For instance, the co-
crystallized ligands in 4BDS (Nachon et al., 2013) and 4B0O
(Wandhammer et al., 2013) were retrieved with a RMSD of
0.37 and 1.65 Å respectively. In agreement with the crystallized
structure, the binding mode retrieved by the ligand tacrine in
4BDS located the heterocyclic scaffold near the residue Trp82
and established π-π stacking interactions with the residue. In
the 4B0O structure, the pose described by docking retrieved the
π-π stacking interactions between the benzylpyridinium group
of the ligand and residues Trp82 and Tyr332. In addition, the
trichloroacetimidate is oriented toward the same area in the
receptor close to residues Thr120 and Ser287.
After docking simulations, all the compounds in our
series yielded a similar binding mode that directed the
triphenylphosphonium group toward the bottom of the pocket,
close to the catalytic triad characterized by residues Ser198,
Glu325 and His438, whereas the hydroxybenzamide was
positioned toward the surface of the cavity (Figure 6). The
most active compound in the series (AntiOxBEN1) established
a hydrogen bond between the nitrogen of the amide group and
the residue Asn68. The binding mode also yielded additional
hydrogen bonds with residues Asn68 and Glu276 by anchoring
with the hydroxyl groups of the phenyl ring. Additionally,
AntiOxBEN1 establishedπ-π stacking andπ-cation interactions
between the triphenylphosphonium group and residues Phe329
and Trp82. The residue Trp82 in the anionic site has been
previously described as a key residue that establishes π-
cation interactions with choline scaffolds (Nicolet et al., 2003;
Bacalhau et al., 2016). A similar binding mode was detected
for AntiOxBEN2 with three hydroxyl groups in the phenyl
ring. The introduction of a third hydroxyl group in the phenyl
ring originated an additional hydrogen bond with the residue
Asn289 (Figure 6). However, the hydroxyphenyl ring is slightly
shifted toward the residue Asn289 causing the disruption
of the hydrogen bond with residue Asn68. This fact could
be related with the reduction of inhibitory activity shown
by AntiOxBEN2 in comparison to AntiOxBEN1. Moreover,
Coulomb interactions could play an important role in the ligand-
protein recognition since there are different charged residues in
the protein pocket and the studied compounds bear a positive
charge in the phosphonium group. We calculated the Coulomb
residue contributions to the binding for AntiOxBEN1 and
AntiOxBEN2. The key contribution of some residues to the
binding is represented in Figure 6D. Some residues showed
important contributions, such as Glu276, Glu197, SBG198
(conjugated Ser in the aged enzyme), and Asp70. AntiOxBEN1
and AntiOxBEN2 presented some differences in the Coulomb
energies for residues Glu276 and Asn289. While AntiOxBEN2
showed a noticeable reduction of Coulomb interactions with
residue Glu276 compared to AntiOxBEN1, the interactions with
the residue Asn289 were higher. The introduction of additional
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FIGURE 6 | (A) General perspective of AntiOxBEN1 (CPK representation) bound to the BChE (ribbons) extracted from molecular docking; (B) Binding mode
calculated with molecular docking for AntiOxBEN1 (pink carbons) in the BChE (color code: yellow dashes for hydrogen bonds, blue dashes for π-π stacking
interactions and green dashes for π-cation interactions); (C) Pose yielded by docking for AntiOxBEN2 (blue carbons) in the BChE; and (D) Coulomb residue
contributions to the binding between the BChE and AntiOxBEN1 and AntiOxBEN2.
FIGURE 7 | (A) General overview with compounds AntiOxBEN1 and 17 (pink and green carbons respectively) bound to BChE after docking simulations; and (B)
Comparison of the hypothetical binding modes determined for compounds AntiOxBEN1 (pink carbons) and 17 (green carbons) inside the BChE (color code: yellow
dashes for hydrogen bonds, blue dashes for π-π stacking interactions and green dashes for π-cation interactions).
hydroxyl groups in the phenyl scaffold could be responsible for
both the disruption and formation of ligand-protein interactions
with a final decreased effect in the experimental activity.
Moreover, the position of the third hydroxyl group is close to
some hydrophobic residues, such as Leu286 and Val288 that
define the acyl-binding pocket in the BChE. Polar substituents
near this region could contribute to reduce the energy binding.
On the other hand, the enlargement of the aliphatic chain
caused a slight reduction of the BChE activity. Molecular docking
showed a binding mode for compound 17 with some differences
regarding AntiOxBEN1. Since compound 17 has an extended
spacer length, the protein pocket accommodated the compound
in a different binding position that could be responsible for
the reduction of the activity. The hydroxybenzamide group was
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accommodated in a shallower region of the protein pocket and
established hydrogen bonds with the residue Ala277 (Figure 7).
However, the different position of the hydroxybenzamide scaffold
did not yield hydrogen bonds with residues Asn68 and Glu276
as AntiOxBEN1. The proposed different binding mode for
compound 17, due to the enlargement of the aliphatic chain
between the triphenylphosphonium and the hydroxybenzamide
groups, could be responsible for the reduction of BChE activity.
According to molecular modeling studies, this type of
mitochondriotropic antioxidants are able to interact with both
catalytic active site (CAS) and PAS of BChE and so they can act
as bifunctional inhibitors (Brunhofer et al., 2012; Eckroat et al.,
2013).
CONCLUSION
For the first time, dual target compounds based on
mitochondriotropic antioxidants endowed with cholinesterase
bifunctional inhibitory activity were described.
AntiOxBEN1 acted as a selective and non-competitive BChE
inhibitor and compounds 15–18 showed similar antioxidant and
ChE inhibitory activities, when compared to AntiOxBEN1 and
AntiOxBEN2. From the series, AntiOxBEN1 and compound
18 were the most promising BChE and/or AChE inhibitors,
respectively, acting by a non-competitive mechanism. Moreover,
these compounds did not exhibit cytotoxic effects in both
SH-SY5Y and HepG2 cells and significantly prevented Aβ1–
42 peptide-induced dysfunction/cell death. Dual inhibition
may also help to slow down the formation of amyloidogenic
compounds, providing an important neuroprotective disease-
modifying effect.
According to the BChE selectivity and antioxidant
properties as well as drug-like properties, which points
toward BBB permeability, and favorable toxicological
profile the mitochondriotropic antioxidant AntiOxBEN1
is considered a valid candidate for the development
of a dual acting drugs useful for AD therapy, which
should be validated in animal models relevant for the
disease.
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